Headquartered in Austin, TX·Fiscal year ends December·NASDAQ: SAVA·cassavasciences.com
About Cassava Sciences
Filana Therapeutics, Inc. (NASDAQ: FLNA) is a clinical-stage biotechnology company developing investigational therapies that modulate the filamin A protein. It targets central nervous system disorders and other diseases associated with dysregulation or overexpression of filamin A. Its lead candidate, simufilam, is an oral small molecule being advanced for Tuberous Sclerosis Complex (TSC)-related epilepsy, a rare genetic seizure disorder linked to TSC1/TSC2 mutations and the mTOR pathway. The disorder affects an estimated 45,000 people in the U.S. In September 2026 the FDA lifted a clinical hold on the simufilam IND for this indication. The company is now preparing a roughly 40-patient, randomized, double-blind Phase 2a study at about 13 U.S. sites, with patient screening expected by Q1 2027. Filana has no approved products and generates no revenue. It funds operations from its cash balance, has no debt, and has placed funds in escrow related to a potential settlement of securities litigation. Updated
Meme stocks traded well-mixed at midday Thursday. The morning's most surprising turn came from a stock that missed estimates and gave lower guidance but still traded higher.
U.S. retail investors now own 12 times more stock than do hedge funds, and Americans have a greater percentage of their money in savings and stock portfolios than at any time since…
A federal investigation into one company's research data has caused its stock to crater, while a rebuttal of a short seller's claims have lifted another.
A company developing a treatment for Alzheimer's disease got a big boost Thursday when a journal in which the company published a report said it found no basis for allegations of data…
Filana Therapeutics, Inc. (NASDAQ: FLNA) is a clinical-stage biotechnology company developing investigational therapies that modulate the filamin A protein. It targets central nervous system disorders and other diseases associated with dysregulation or overexpression of filamin A.
What is the SAVA stock price target?
The Wall Street consensus 12-month price target for SAVA is $8.00.